Development and characterization of an ETV1 rabbit monoclonal antibody for the immunohistochemical detection of ETV1 expression in cancer tissue specimens.

[1]  E. Small,et al.  The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression , 2022, bioRxiv.

[2]  C. Loveridge,et al.  Evaluation of the Suitability of RNAscope as a Technique to Measure Gene Expression in Clinical Diagnostics: A Systematic Review , 2021, Molecular diagnosis & therapy.

[3]  A. Chinnaiyan,et al.  Molecular profiling of ETS and non‐ETS aberrations in prostate cancer patients from northern India , 2021, The Prostate.

[4]  I. Kurnaz,et al.  Gene Regulatory Network of ETS Domain Transcription Factors in Different Stages of Glioma , 2021, Journal of personalized medicine.

[5]  S. Srivastava,et al.  Prognostic features of Annexin A2 expression in prostate cancer. , 2020, Pathology.

[6]  J. Pižem,et al.  A novel PTPRZ1‐ETV1 fusion in gliomas , 2020, Brain pathology.

[7]  M. Fassan,et al.  Identification of long intergenic non-coding RNAs (lincRNAs) deregulated in gastrointestinal stromal tumors (GISTs) , 2018, PloS one.

[8]  M. Marra,et al.  Transcriptomic analysis of CIC and ATXN1L reveal a functional relationship exploited by cancer , 2018, Oncogene.

[9]  G. Fishman,et al.  ETV1 activates a rapid conduction transcriptional program in rodent and human cardiomyocytes , 2018, Scientific Reports.

[10]  P. Zoppoli,et al.  Identification of different mutational profiles in cancers arising in specific colon segments by next generation sequencing , 2018, Oncotarget.

[11]  W. Kim,et al.  Gastrointestinal stromal tumor of unusual phenotype after imatinib treatment , 2017, Medicine.

[12]  C. Antonescu,et al.  Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and Molecular Study of 115 Cases , 2017, The American journal of surgical pathology.

[13]  C. Antonescu,et al.  ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with CIC gene rearrangements , 2017, Genes, chromosomes & cancer.

[14]  Jared L Spidel,et al.  Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins , 2017, mAbs.

[15]  Min Hye Lee,et al.  Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascade , 2017, The Journal of pathology.

[16]  Dafydd G. Thomas,et al.  The utility of ETV1, ETV4 and ETV5 RNA in‐situ hybridization in the diagnosis of CIC–DUX sarcomas , 2017, Histopathology.

[17]  Weihong Song,et al.  Estrogen receptor α (ERα) status evaluation using RNAscope in situ hybridization: a reliable and complementary method for IHC in breast cancer tissues. , 2017, Human pathology.

[18]  S. Asthana,et al.  Inactivation of Capicua drives cancer metastasis , 2016, Nature Genetics.

[19]  Xiao-Jun Ma,et al.  Fully Automated RNAscope In Situ Hybridization Assays for Formalin‐Fixed Paraffin‐Embedded Cells and Tissues , 2016, Journal of cellular biochemistry.

[20]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[21]  F. Ducray,et al.  CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas , 2015, Annals of neurology.

[22]  W. Kim,et al.  ETV1 mRNA is specifically expressed in gastrointestinal stromal tumors , 2015, Virchows Archiv.

[23]  R. Blunck,et al.  Reinitiation at non-canonical start codons leads to leak expression when incorporating unnatural amino acids , 2015, Scientific Reports.

[24]  Christopher Tan,et al.  Expression of Kit and Etv1 in restricted brain regions supports a brain-cell progenitor as an origin for cranial germinomas. , 2015, Cancer genetics.

[25]  J P Landry,et al.  Measuring affinity constants of 1450 monoclonal antibodies to peptide targets with a microarray-based label-free assay platform. , 2015, Journal of immunological methods.

[26]  R. Lothe,et al.  Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts , 2015, Oncotarget.

[27]  T. Wilkinson,et al.  Generation of potent mouse monoclonal antibodies to self-proteins using T-cell epitope “tags” , 2014, mAbs.

[28]  Y. Totoki,et al.  A Novel CIC-FOXO4 Gene Fusion in Undifferentiated Small Round Cell Sarcoma: A Genetically Distinct Variant of Ewing-like Sarcoma , 2014, The American journal of surgical pathology.

[29]  C. Pirker,et al.  MAP kinase activity supported by BRAFV600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases , 2014, Archives of Dermatological Research.

[30]  S. Dhanasekaran,et al.  Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. , 2013, Translational oncology.

[31]  Rui Henrique,et al.  Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer. , 2013, Neoplasia.

[32]  M. Loda,et al.  ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. , 2013, Genes & development.

[33]  M. Isobe,et al.  Rapid production of antigen-specific monoclonal antibodies from a variety of animals , 2012, BMC Biology.

[34]  Joshua J. Steffan,et al.  The Transcription Factor SPDEF Suppresses Prostate Tumor Metastasis* , 2012, The Journal of Biological Chemistry.

[35]  J. Flanagan,et al.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.

[36]  J. Lasota,et al.  Histopathology of gastrointestinal stromal tumor , 2011, Journal of surgical oncology.

[37]  Yuchen Jiao,et al.  Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma , 2011, Science.

[38]  Peter C. Hollenhorst,et al.  Genomic and biochemical insights into the specificity of ETS transcription factors. , 2011, Annual review of biochemistry.

[39]  A. de Klein,et al.  Overexpression of Full-Length ETV1 Transcripts in Clinical Prostate Cancer Due to Gene Translocation , 2011, PloS one.

[40]  M. Rubin,et al.  Testing mutual exclusivity of ETS rearranged prostate cancer , 2010, Laboratory Investigation.

[41]  C. Antonescu,et al.  ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours , 2010, Nature.

[42]  S-H Tan,et al.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.

[43]  Yanfang Wu,et al.  Generation of Monoclonal Antibodies against Highly Conserved Antigens , 2009, PloS one.

[44]  T. Pearson,et al.  Anti-peptide antibody screening: selection of high affinity monoclonal reagents by a refined surface plasmon resonance technique. , 2009, Journal of immunological methods.

[45]  T. H. van der Kwast,et al.  Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer. , 2008, Cancer research.

[46]  J. Cuzick,et al.  Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer , 2008, British Journal of Cancer.

[47]  R. Shah,et al.  Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.

[48]  J. Reis-Filho,et al.  Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas , 2008, Journal of Clinical Pathology.

[49]  S. Varambally,et al.  Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. , 2008, Cancer research.

[50]  A. Chinnaiyan,et al.  Recurrent gene fusions in prostate cancer , 2008, Nature Reviews Cancer.

[51]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[52]  Debashis Ghosh,et al.  Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.

[53]  Arul M Chinnaiyan,et al.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. , 2006, Cancer research.

[54]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[55]  A. D. Tos,et al.  Rabbit Monoclonal Antibodies , 2005 .

[56]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.

[57]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[58]  Peter C. Hollenhorst,et al.  Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. , 2004, Nucleic acids research.

[59]  D. Watson,et al.  Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. , 2003, The American journal of pathology.

[60]  V. Sementchenko,et al.  Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. , 2003, Cancer research.

[61]  K. Okumura,et al.  Humanization and Epitope Mapping of Neutralizing Anti-Human Fas Ligand Monoclonal Antibodies: Structural Insights into Fas/Fas Ligand Interaction1 , 2001, The Journal of Immunology.

[62]  M. Vidaud,et al.  Characterization of the human and mouse ETV1/ER81 transcription factor genes: role of the two alternatively spliced isoforms in the human , 1999, Oncogene.

[63]  S J Schnitt,et al.  Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Martin Rosenberg,et al.  A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer , 1997, Oncogene.

[65]  K L Knight,et al.  Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[66]  C. Denny,et al.  A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. , 1995, Oncogene.

[67]  P. Tongaonkar,et al.  A semi‐empirical method for prediction of antigenic determinants on protein antigens , 1990, FEBS letters.

[68]  J. Wells,et al.  High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. , 1989, Science.

[69]  T. Raybould,et al.  Production of stable rabbit-mouse hybridomas that secrete rabbit mAb of defined specificity. , 1988, Science.

[70]  E. Adamson,et al.  Preparation and properties of monoclonal and polyclonal antibodies to mouse epidermal growth factor (EGF) receptors: evidence for cryptic EGF receptors in embryonal carcinoma cells. , 1987, Development.

[71]  J. Bystryn,et al.  Comparison of cell-surface human melanoma-associated antigens identified by rabbit and murine antibodies. , 1982, Hybridoma.

[72]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.